Stifel Initiates Coverage On Enliven Therapeutics with Buy Rating, Announces Price Target of $60

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

Stifel analyst Dara Azar initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Buy rating and announces Price Target of $60.